DRNA - Dicerna Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.32
-1.01 (-7.05%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.33
Open14.62
Bid0.00 x 900
Ask0.00 x 800
Day's Range13.28 - 14.47
52 Week Range9.31 - 17.98
Volume488,233
Avg. Volume408,657
Market Cap910.555M
Beta (3Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-1.38
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.71
Trade prices are not sourced from all markets
  • BioBoyScout’s Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR)
    Insider Monkey

    BioBoyScout’s Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR)

    BioBoyScout, founded by Intellectual Property attorney Robert Toczycki, JD, MBA, has developed online biotech valuation calculators that enable small investors to compete with the big Wall Street institutions. The calculators can be modified to a user’s liking and apply the same financial valuation models used by most Wall Street analysts. BioBoyScout began developing its models […]

  • Thomson Reuters StreetEvents

    Edited Transcript of DRNA earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Dicerna Pharmaceuticals Inc Earnings Call

  • Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript

    DRNA earnings call for the period ending June 30, 2019.

  • Business Wire

    Dicerna™ Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    — Strengthened Management with Senior Hires Across Medical Affairs, Commercial, Regulatory, and Patient Advocacy and Patient Services —

  • Business Wire

    Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 218,500 shares of common stock to be distributed among six new employees, with a grant date of August 1, 2019 (the “Inducement Grant"). The stock options approved under the Inducement Grant were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $13.46, the fair market value on the grant date.

  • Business Wire

    Dicerna™ to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

    Dicerna™ Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Company will release its second quarter 2019 financial results after market close on Thursday, August 8, 2019.

  • Steven Cohen Charges Into Chiasma
    GuruFocus.com

    Steven Cohen Charges Into Chiasma

    Guru invests in clinical-stage biopharmaceutical company Continue reading...

  • Business Wire

    Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1)

    DicernaTM Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to DCR-PHXC for the treatment of patients with primary hyperoxaluria type 1 (PH1). DCR-PHXC is the only RNAi investigational therapy in development for the treatment of all types of PH, a family of severe, rare, inherited disorders of the liver that often result in kidney failure.

  • 5 Stocks With Over 20% Upside Potential, Say Top Analysts
    TipRanks

    5 Stocks With Over 20% Upside Potential, Say Top Analysts

    The market is now at record levels. And according to Barclays, the rally isn’t going to stop anytime soon. The firm now sees a 65% chance the S&P 500 will surge 10% higher from current levels. “After the truce in the U.S.-China trade war post the G-20 meeting in Osaka, the ‘melt-up’ scenario ... is now our highest probability outcome,” says Maneesh Deshpande, head of equity derivatives strategy at Barclays.Deshpande adds that he believes two bullish catalysts will help push shares higher. First he is confident that the Fed will still embark on an easing cycle. “The weakness in global manufacturing continues unabated and the subdued inflation and softening inflation expectations will likely prompt some ‘insurance cuts’ from the Fed” says the analyst.At the same time “the current manufacturing weakness is unlikely to morph into a full recession given the resilience in the services sector of the economy,” says Deshpande.So with this bullish outlook in mind, which stocks are primed to swing higher? Here we turned to the Street to see which stocks analysts believe still have plenty of growth potential ahead. That’s according to the upside potential from the average analyst price target. Let’s see how that works out now: 1\. VMware (VMW)Software stock VMware virtualizes computing, from the data center to the cloud to mobile. For its customers, VMware can help lower IT costs, provide more flexibility, and offer more automated and resilient systems. Shares in the Dell (DELL) subsidiary are up 23% year-to-date, with the company delivering a robust first quarter despite not raising guidance.Most excitingly, VMware will now run on Microsoft’s (MSFT) Azure public cloud. The news, announced back in April, comes after a similar deal was struck with heavyweight Amazon's (AMZN) Amazon Web Services (AWS) three years ago. According to Wedbush analyst Daniel Ives, “VMW is looking to position itself as the key engine and virtualization platform; a clear catalyst for growth heading into FY20 and beyond in our opinion.” He has just reiterated his buy rating on the stock with a $210 price target (24% upside potential). “In a nutshell we remain very positive on VMware's technology and execution and believe it is uniquely well positioned to be a clear leader in enabling hybrid cloud deployments” writes Ives.Over the last three months, 13 analysts have published buy ratings on the stock vs 3 hold ratings. With an average price target of $215, analysts are looking for upside potential of 27%. View VMW Price Target & Analyst Ratings Detail 2\. Dicerna (DRNA)This biopharma has already soared over 38% year-to-date, but according to the Street sizable upside potential continues to lie ahead. In the last week, four analysts reiterated their buy ratings on Dicerna stock. That’s after the company unveiled its rare liver disease program for the treatment of alpha-1 antitrypsin (A1AT) deficiency (AATD).Analysts reacted positively to the announcement. “The choice of AATD as first entry into a rare, genetic liver disease makes a lot of sense on multiple levels” sums up HC Wainwright’s Ed Arce. For example, AATD is an indication with a significant unmet medical need (no approved therapies; severe cases can be life-threatening), while also presenting a rapid and efficient development path to approval.The analyst continues: “We view this as another key milestone, not just in further solidifying a track record of execution, but more importantly, in the long-term growth plan of a rapidly expanding and maturing company that we believe represents a core, pure-play holding in the greater nucleic acid therapy space.”Taking a step back we can see that his bullish tone is reflected by the Street. Seven analysts have published recent buy ratings on the stock, and their $22 average price target suggests impressive upside potential of 47%. View DRNA Price Target & Analyst Ratings Detail 3\. Columbia Sportswear (COLM)Five-star Guggenheim analyst Robert Drbul has just hosted meetings in Kansas City and Chicago with the COLM management team including CEO Tim Boyle and Director Andrew Burns. With a price target of $125, Drbul sees shares ripping 24% higher over the coming months. He is encouraged by ongoing strong momentum and sees footwear as a sizable opportunity for the company. That’s because right now it only represents about 22% of the company’s business today. And looking ahead, COLM’s goal is to double footwear in 3 to 5 years under the leadership of Peter Ruppe.“We continue to believe COLM is one of the more attractive growth names in our group, with significant long-term top-line growth and operating margin expansion opportunities, while the company continues to invest in demand creation in an effort to improve consumer demand” enthuses the analyst. Overall, 7 analysts have published buy ratings on the stock, with only 1 analyst staying on the sidelines. Meanwhile the average analyst price target of $121 indicates 20.5% upside potential from current levels. View COLM Price Target & Analyst Ratings Detail 4\. GW Pharma (GWPH)If you haven’t heard of GW Pharma before, this is one of the world’s most prominent cannabis companies. British-based GWPH developed the first ever cannabis plant-derived medicine to receive FDA approval. Called Epidiolex, the drug treats seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome, two rare and severe drug-resistant epilepsy syndromes.So far the company’s Epidiolex launch has proved tremendously successful. For example, the drug’s first quarter sales of $33.5 million sailed past the expected figure of just $20.7 million. Top Piper Jaffray analyst Danielle Brill commented, "expectations for this launch have been sky high - and GWPH continues to deliver.” Brill is optimistic for the company’s outlook, writing: “We think the growth trajectory will continue over the coming quarters given expected EU launch, ongoing dose-titrations, increasing penetration into adult population, transition of remaining expanded access program patients to commercial product, and expansion into new indications." With this in mind, she reiterated her buy rating and $210 price target (22% upside potential). In fact this is slightly more conservative than the Street’s average analyst price target of $220 (28% upside potential). Ten analysts are covering the stock right now; all rate GWPH a ‘buy.’ View GWPH Price Target & Analyst Ratings Detail 5\. Alibaba (BABA)It’s all change over at Chinese e-commerce king Alibaba. The company recently announced that CFO Maggie Wu will replace Executive Vice Chair Joe Tsai as head of strategic acquisitions and investments. That’s as the company reorganizes several business divisions including DingTalk and Freshippo. Separately, in a recent 6-K filing, Alibaba proposed a one-for-eight stock split, to increase “flexibility in the company’s capital raising activities, including the issuance of new shares.”Following the news, top-rated Stifel Nicolaus analyst Scott Devitt reiterated his bullish outlook on the stock. “We recently added shares of BABA to the Stifel Select List and continue to recommend the idea for investors with long-term investment horizons” said the analyst.He approves of the recent developments at BABA. For, example, the analyst writes of Maggie Wu’s new appointment: “Wu has been CFO since 2013 and first joined Alibaba in 2007; we view her increased responsibilities at the top of the organization as a natural progression in the company’s leadership.”More importantly, he views the stock split proposal as a step towards a reported Hong Kong listing. Indeed, Alibaba recently filed confidential paperwork for a listing on the Hong Kong stock exchange with plans to raise as much as $20B, according to multiple news reports. “New capital could be deployed for buybacks or to extend the company’s competitive lead” contends Devitt. “Investors in mainland China, who can buy and sell Hong Kong-listed stocks through a cross-boundary trade link, could also stimulate demand for shares” the analyst added. In total the company has received 15 back-to-back buy ratings from the Street over the last three months. They are predicting (on average) 28% upside potential from current levels. View BABA Price Target & Analyst Ratings DetailGo to TipRanks' Stock Screener to find your own 'Strong Buy' stocks

  • RNAi startup Dicerna developing new liver drug
    American City Business Journals

    RNAi startup Dicerna developing new liver drug

    Three years after shutting down development of its first cancer drug, gene-silencing startup Dicerna Therapeutics is charging forward with its plans to develop drugs for liver disease. Dicerna pivoted its attention to drugs that target the liver after stopping development of its tumor-fighting drug when it reported underwhelming results in two early-stage clinical trials in 2016.

  • Business Wire

    Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    DicernaTM Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced it submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA) last week to conduct a first-in-human Phase 1/2 study of DCR-A1AT, an investigational therapy from the Company’s GalXC™ technology platform, for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease. A1AT deficiency is a genetic disorder that can cause liver disease in children and adults, leading to complications such as weight loss, fatigue, jaundice and life-threatening conditions such as cirrhosis.

  • Business Wire

    Dicerna™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 529,500 shares of common stock to be distributed among 10 new employees, with a grant date of July 1, 2019 (the “Inducement Grant"). Rob Ciappenelli, chief commercial officer of Dicerna, received inducement options to purchase 300,000 of the 529,500 total shares of common stock.

  • Business Wire

    Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

    DicernaTM Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced updated data from its ongoing PHYOX™1 Phase 1 clinical trial evaluating DCR-PHXC, the Company’s lead GalXC™ product candidate. Investigators reported additional results evaluating DCR-PHXC in patients with primary hyperoxaluria type 1 (PH1) and type 2 (PH2), building on previously disclosed data showing substantial reductions in 24-hour urinary oxalate levels following a single-dose of DCR-PHXC.

  • Business Wire

    Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria

    – Prof. Bernd Hoppe, M.D., Appointed Vice President, Global Medical Affairs at Dicerna –

  • Did The Underlying Business Drive Dicerna Pharmaceuticals's (NASDAQ:DRNA) Lovely 393% Share Price Gain?
    Simply Wall St.

    Did The Underlying Business Drive Dicerna Pharmaceuticals's (NASDAQ:DRNA) Lovely 393% Share Price Gain?

    Investing can be hard but the potential fo an individual stock to pay off big time inspires us. You won't get it right...

  • Business Wire

    Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy

    — Steven Kates, Ph.D., Joins Company as Vice President, Regulatory Affairs —

  • Bain's second life sciences fund comes in over $1 billion
    American City Business Journals

    Bain's second life sciences fund comes in over $1 billion

    Bain Capital has unveiled an approximately $1.1 billion life sciences fund, its second targeting the fast-growing industry, a spokesperson for the private equity giant said Wednesday. As a private equity firm, it generally makes later-stage investments than many of the venture capital firms that target the biotech sector.

  • Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA)
    Insider Monkey

    Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA)

    At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of March 31. In this […]

  • Business Wire

    Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer

    — Company Expands Management Team and Bolsters Commercial Capabilities to Support Continued Growth —

  • Business Wire

    Dicerna™ to Present at the Jefferies 2019 Healthcare Conference

    Dicerna™ Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M.

  • Business Wire

    Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus

    The Company anticipates human proof-of-concept data from the Phase 1 trial, which is known as DCR-HBVS-101, in the fourth quarter of 2019. “Dosing of the first patient in the DCR-HBVS-101 trial signals a major step toward our ultimate goal of developing a viable therapeutic option for patients with chronic hepatitis B virus, a serious liver infection that can result in advanced liver disease or liver cancer if not treated effectively,” said Ralf Rosskamp, M.D., chief medical officer of Dicerna.

  • Thomson Reuters StreetEvents

    Edited Transcript of DRNA earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Dicerna Pharmaceuticals Inc Earnings Call

  • Dicerna Pharmaceuticals Inc (DRNA) Q1 2019 Earnings Call Transcript
    Motley Fool

    Dicerna Pharmaceuticals Inc (DRNA) Q1 2019 Earnings Call Transcript

    DRNA earnings call for the period ending March 31, 2019.

  • Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates

    Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -72.73% and -70.67%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?